Author Correction: Phenome-Wide Analysis of Copy Number Variants in 470,727 UK Biobank Genomes

Why It Matters

Accurate attribution reinforces scientific credibility and highlights the scale of collaborative genomics that can drive new therapeutic insights. The corrected record ensures stakeholders correctly recognize the expertise behind a dataset that reshapes disease‑gene mapping.

Key Takeaways

• Correction updates author contributions for massive CNV study
• Study examined CNVs in 470,727 UK Biobank participants
• Findings enhance understanding of genetic variation and disease risk
• Open-access license permits non-commercial sharing of the research
• Collaboration spans AstraZeneca sites worldwide and academic institutions

Pulse Analysis

The corrected Nature paper represents one of the most extensive phenome‑wide investigations of copy‑number variants to date. By leveraging the UK Biobank’s half‑million‑strong genomic repository, researchers were able to map structural variations to dozens of clinical traits, uncovering novel genotype‑phenotype relationships that were previously invisible in smaller cohorts. This scale of analysis not only refines the catalog of pathogenic CNVs but also provides a statistical backbone for future studies seeking to translate structural genomics into actionable health insights.

AstraZeneca’s involvement underscores the growing convergence between pharmaceutical R&D and large‑scale population genetics. The consortium’s multidisciplinary team, spanning sites in the UK, US, Sweden, China, and beyond, integrated bioinformatics, clinical expertise, and drug discovery pipelines to assess how CNVs influence disease pathways and therapeutic response. Such collaborations accelerate the identification of high‑value targets, inform patient stratification strategies, and support the development of precision medicines that address genetic risk factors uncovered by the study.

Issuing an author correction may seem procedural, yet it reflects a broader commitment to research integrity and transparency. Accurate author attribution ensures that credit—and accountability—are properly assigned, which is vital for fostering trust among collaborators, funders, and the scientific community. Moreover, the open‑access licensing facilitates widespread, non‑commercial dissemination, enabling clinicians, researchers, and policy makers to build upon these findings without legal barriers, thereby amplifying the study’s impact on public health and future genomic initiatives.